Senseonics (NASDAQ:SENS) Stock: Insider Douglas Roeder Buys 17,041 Shares

Senseonics Holdings, Inc. (NASDAQ:SENS – Get Free Report) Director Douglas Roeder acquired 17,041 shares of the firm’s stock in a transaction that occurred on Friday, November 13th. The stock was bought at an average cost of $10.32 per share, with a total value of $175,863.12. Following the completion of the transaction, the director directly owned 189,712 shares in the company, valued at $1,957,827.84. The trade was a 9.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Senseonics Stock Performance

NASDAQ:SENS traded up $0.32 during trading hours on Monday, hitting $10.90. 2,629,528 shares of the company were exchanged, compared to its average volume of 703,179. The stock has a market capitalization of $455.65 million, a price-to-earnings ratio of -4.74 and a beta of 1.04. Senseonics Holdings, Inc. has a 52-week low of $4.79 and a 52-week high of $13.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.92 and a quick ratio of 5.60. The company’s 50 day moving average price is $9.17 and its 200-day moving average price is $7.33.

Senseonics (NASDAQ:SENS – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). The company had revenue of $19.56 million during the quarter. Senseonics had a negative return on equity of 186.11% and a negative net margin of 204.01%. As a group, research analysts forecast that Senseonics Holdings, Inc. will post -2.20 earnings per share for the current year.

Institutional Trading of Senseonics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Empowered Funds LLC acquired a new stake in shares of Senseonics in the third quarter worth $621,000. Ieq Capital LLC acquired a new position in Senseonics during the third quarter valued at $215,000. StoneX Group Inc. acquired a new position in Senseonics during the third quarter valued at $128,000. Traynor Capital Management Inc. acquired a new position in Senseonics during the third quarter valued at $152,000. Finally, State of Wyoming boosted its holdings in Senseonics by 27.2% in the third quarter. State of Wyoming now owns 14,940 shares of the company’s stock valued at $152,000 after purchasing an additional 3,199 shares during the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SENS shares. Barclays raised their target price on Senseonics from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 10th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Senseonics in a research note on Tuesday, November 10th. Stifel Nicolaus reissued a “hold” rating and issued a $10.00 price objective (up from $9.00) on shares of Senseonics in a report on Tuesday, November 10th. Weiss Ratings upgraded Senseonics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Finally, Mizuho lifted their target price on Senseonics from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, November 10th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $14.40.

Read Our Latest Analysis on SENS

About Senseonics

(Get Free Report)

Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.

Featured Articles

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.